1. Home
  2. TBPH vs ESPR Comparison

TBPH vs ESPR Comparison

Compare TBPH & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$19.87

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.45

Market Cap

898.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
ESPR
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
898.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
TBPH
ESPR
Price
$19.87
$3.45
Analyst Decision
Strong Buy
Buy
Analyst Count
5
6
Target Price
$27.80
$6.67
AVG Volume (30 Days)
376.6K
5.8M
Earning Date
02-25-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$80,327,000.00
$303,802,000.00
Revenue This Year
$70.78
$27.49
Revenue Next Year
N/A
N/A
P/E Ratio
$32.64
N/A
Revenue Growth
27.12
2.83
52 Week Low
$7.90
$0.69
52 Week High
$21.03
$4.18

Technical Indicators

Market Signals
Indicator
TBPH
ESPR
Relative Strength Index (RSI) 54.78 50.34
Support Level $18.78 $3.06
Resistance Level $21.03 $3.52
Average True Range (ATR) 0.81 0.22
MACD -0.15 0.03
Stochastic Oscillator 45.60 76.28

Price Performance

Historical Comparison
TBPH
ESPR

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Share on Social Networks: